Irinotecan Hydrochloride Accord-Uk (Irinotecan Hydrochloride Trihydrate)

After infusion, irinotecan is metabolised to SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing tumour cell death.

The prescribed dose of Irinotecan is individualized by the treating oncologist based on factors such as patient body surface area, liver function, prior chemotherapy exposure, and the specific combination protocol being used. No fixed dosing schedule is provided here.

The safety of Irinotecan during pregnancy or lactation has not been established. It should only be used if the potential therapeutic benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Enquiries can be submitted on the product page at gnhindia.com by specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and the necessary import documentation.

The primary alternative within the same class is topotecan, another topoisomerase I inhibitor. Irinotecan generally shows higher activity in colorectal and gastrointestinal tumours, while topotecan is more commonly used for ovarian and small‑cell lung cancers. Compared with oxaliplatin‑based regimens, Irinotecan offers a different toxicity profile, with more pronounced diarrhoea and neutropenia but less peripheral neuropathy.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified in the product label.

Irinotecan is given as an intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified personnel, with appropriate monitoring for infusion‑related reactions and supportive care measures.

The most critical adverse events include severe neutropenia (which can lead to infection), life‑threatening diarrhoea or colitis, febrile neutropenia, hepatic toxicity, and rare but serious allergic reactions. Prompt medical attention is required if fever, persistent diarrhoea, or signs of infection develop.

Patients with known hypersensitivity to irinotecan or any of its excipients should avoid the drug. It is also contraindicated in individuals with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment without dose adjustment. Clinical judgment is required for patients with pre‑existing gastrointestinal disorders.